You are here

Article Text

Article menu
Download PDFPDF
Letter
Rituximab for the treatment of extranodal marginal zone B-cell lymphoma of the lacrimal gland
  1. Carsten Heinz1,
  2. Hartmut Merz2,
  3. Matthias Nieschalk3,
  4. Heribert Mueller-Miny4,
  5. Peter Koch5,
  6. Arnd Heiligenhaus6
  1. 1
    Department of Ophthalmology, St. Franziskus-Hospital Muenster, Muenster, Germany and Department of Ophthalmology, University of Duisburg-Essen, Duisburg, Germany
  2. 2
    Department of Pathology, University of Schleswig-Holstein, Luebeck, Germany
  3. 3
    Department of ENT, St. Franziskus-Hospital Muenster, Muenster, Germany
  4. 4
    Department of Radiology, St. Franziskus-Hospital Muenster, Muenster, Germany
  5. 5
    Department of Medicine Haematology/Oncology, University of Muenster, Muenster, Germany
  6. 6
    Department of Ophthalmology, St. Franziskus-Hospital Muenster, Muenster, Germany and Department of Ophthalmology, University of Duisburg-Essen, Duisburg, Germany
  1. Dr Carsten Heinz, Department of Ophthalmology, St. Franziskus-Hospital Muenster, Hohenzollernring 54, 48145 Muenster, Germany; carsten.heinz{at}uveitis-zentrum.de

http://dx.doi.org/10.1136/bjo.2007.115626

Statistics from Altmetric.com

    Extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) of the lacrimal gland is a rare condition. Treatment options chiefly include radiation of the tumour, chemotherapy, surgical removal or a combination of these strategies.1 Radiation therapy is associated with a high risk of ocular morbidity, especially dry eye.1 Here, we report a case of a biopsy-proven extranodal MALT lymphoma of the lacrimal gland treated with two courses of four weekly cycles of rituximab.

    Case report

    A 64-year-old woman presented with unilateral ptosis and swelling of her right lacrimal gland. Best-corrected visual acuity was 20/25. Slit-lamp examination showed severe punctate superficial keratopathy (basal secretion 0 mm OU). …

    View Full Text

    Footnotes

    • Competing interests: None.

    • Informed consent was obtained for publication of the person’s details in this report.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    2007 BMJ Publishing Group Ltd